Alkem Laboratories Ltd. · NSE:ALKEM
Alkem Laboratories — Q1 FY2025 Earnings Presentation
17 slides from Alkem Laboratories's earnings presentation, Aug 9, 2024
Slide 1: Cover letter to stock exchanges on Q1FY25 results
ALKEM LABORATORIES LTD. <8> ALKEM Regd. Office: ALKEM HOUSE, Senapati Bapat Marg, Lower Parel (West), Mumbai• 400 013, Maharashtra, India. • Phone: +91-22-3982 9999 • Fax: 022-2495 2955 • Email: contact@alkem.com • Website: www.alkemlabs.com • CIN: L00305MH1973PLC174201 09th August, 2024 To, The Cor
Slide 2: Alkem reports Q1FY25 results
Press Release Alkem reports Q1FY25 results Mumbai, 09 August 2024: Alkem Laboratories Ltd. today announced its standalone and consolidated financial results for the first quarter that ended June 30, 2024. These results were taken on record by the Board of Directors at its meeting held in Mumbai toda
Slide 3: Operational Highlights
Operational Highlights Domestic Business - In Q1FY25, the Company’s India sales increased by 6.4% YoY, recording sales of ₹ 20,223 million compared to ₹ 19,007 million in Q1FY24. • According to IQVIA (SSA) data, for Q1FY25, the Company delivered a YoY growth of 8.4% compared to the Indian Pharmaceut
Slide 4: International Business
International Business - In Q1FY25, the Company’s International sales declined by 4.6% YoY, recording sales of ₹ 9,677 million compared to ₹ 10,146 million in Q1FY24. • US sales for Q1FY25 stood at ₹ 6,416 million, witnessing a decline of 7.7% YoY and a growth of 2.8% on a QoQ basis. • Other Interna
Slide 5: Q1FY25 Conference Call
Q1FY25 Conference Call at 5 pm IST, August 09, 2024 Alkem will organise a conference call for investors and analysts on Friday, August 09, 2024, from 5:00 pm to 6:00 pm IST to discuss its Q1FY25 financial results. Alkem Laboratories Ltd. will be represented on the call by: Dr. Vikas Gupta – CEO Mr N
Slide 6: Investor Presentation Q1FY25
Investor Presentation Q1FY25 August 09, 2024
Slide 7: Safe Harbor Statement
Safe Harbor Statement This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions. Forward-looking statements are all statements that concern plans, objectives, goals, strategies, future events or performance and underlying assumptions and
Slide 8: Key Highlights of Q1FY25
Key Highlights of Q1FY25 • Total Revenue from Operations was ₹ 30,318 million, with YoY growth of 2.2%. o India sales were ₹ 20,223 million, YoY growth of 6.4%. The contribution of domestic sales to total sales in Q1FY25 was 67.6% vs. 65.2% in Q1FY24. o International sales were ₹ 9,677 million, with
Slide 9: Key Financial Highlights – Q1FY25 (Consolidated)
Key Financial Highlights – Q1FY25 (Consolidated) All figures in ₹ Mn Revenue from Operations India sales 19,007 20,223 29,677 30,318 Q1FY24 Q1FY25 International sales 10,146 9,677 Q1FY24 Q1FY25 Q1FY24 Q1FY25
Slide 10: Key Financial Highlights – Q1FY25 (Consolidated)
Key Financial Highlights – Q1FY25 (Consolidated) All figures in ₹ Mn Gross Profit and Gross Margin EBITDA and EBITDA Margin 6,086 19,559 17,692 3,892 59.6% 64.5% 13.1% 20.1% Q1FY24 Q1FY25 Q1FY24 Q1FY25 PBT (after exceptional item) PAT (after Minority Interest) 5,452 6,194 2,867 3,529 9.7% 18.0% Q1FY
Slide 11: India - Secondary Sales Performance
India - Secondary Sales Performance Mixed performance across all major therapeutic segments in Q1FY25 1 3 3 2 Market rank Acute Therapies Anti-infectives Gastro-intestinal Pain/ Analgesics Vitamins/ Minerals / Nutrients 14.3% 12.6% 11.3% 8.2% 8.1% 6.8% 5.9% 3.3% Alkem sales growth YoY1,2 Indian phar
Slide 12: US Business Update
US Business Update Q1FY25 Sales of ₹ 6,416 million (7.7% YoY de-growth) • Overall contribution of US sales to total sales was 21.5% in Q1FY25. • During Q1FY25, the company launched 1 product in the US and received approval for 3 ANDAs from the USFDA, including one tentative approval. • As of June 30
Slide 13: Update on USFDA inspections
Update on USFDA inspections Facility Capability Inspection Date Regulatory Status Baddi (India) Formulations Mar-24 EIR Received in June 2024 Daman (India) Formulations Aug-19 EIR Received in Oct 2019 Taloja R&D (India) Bioequivalence Centre Oct-22 No observation Ankleshwar (India) API Apr-23 EIR Re
Slide 14: Other International Business Update
Other International Business Update Q1FY25 Sales of ₹ 3,261 million (2.2% YoY growth) • Other International Market sales contributed 10.9% to total sales in Q1FY25. • The Company has a presence mainly in Latin America, Australia and Europe. Q1FY25 – Other International Sales (₹ Mn) Q1FY25 – Other In
Slide 15: Shareholding Pattern as on June 30, 2024
Shareholding Pattern as on June 30, 2024 Non-Institution BSE Ticker 539523 16.36% NSE Symbol ALKEM Promoter & Shares Outstanding (Mn) 120 Promoter Group Institution 27.26% 56.38% MCap (Rs in Mn)* 596,791 Free Float Mcap (Rs in Mn) 260,320 Industry Pharmaceuticals Institution – Mutual Funds, Alternat
Slide 16: Key Financial Highlights – Q1FY25 (Consolidated)
Key Financial Highlights – Q1FY25 (Consolidated) All figures in ₹ Mn Particulars Q1FY25 Q1FY24 YoY growth Q4FY24 QoQ growth Revenue from Operations 30,318 29,677 2.2% 29,358 3.3% Gross Profit 19,559 17,692 10.6% 18,284 7.0% Gross Profit Margin 64.5% 59.6% 62.3% EBITDA 6,086 3,892 56.4% 4,020 51.4% E
Slide 17: Thank You
Thank You For any queries, contact: Purvi Shah Mobile: +91 84337 00890 E-mail: purvi.shah@alkem.com Tel: +91 22 3982 9999 Ext: 9447